Adherence to secondary prophylaxis and disease recurrence in 536 Brazilian children with rheumatic fever

Christina F Pelajo, Jorge M Lopez-Benitez, Juliana M Torres, Sheila Kf de Oliveira, Christina F Pelajo, Jorge M Lopez-Benitez, Juliana M Torres, Sheila Kf de Oliveira

Abstract

Background: More than 15 million people worldwide have rheumatic fever (RF) and rheumatic heart disease due to RF. Secondary prophylaxis is a critical cost-effective intervention for preventing morbidity and mortality related to RF. Ensuring adequate adherence to secondary prophylaxis for RF is a challenging task. This study aimed to describe the rates of recurrent episodes of RF, quantify adherence to secondary prophylaxis, and examine the effects of medication adherence to the rates of RF in a cohort of Brazilian children and adolescents with RF.

Methods: This retrospective study took place in the Pediatric Rheumatology outpatient clinic at a tertiary care hospital (Instituto de Puericultura e Pediatria Martagão Gesteira) in Rio de Janeiro, Brazil, and included patients with a diagnosis of RF from 1985 to 2005.

Results: 536 patients with RF comprised the study sample. Recurrent episodes of RF occurred in 88 of 536 patients (16.5%). Patients with a recurrent episode of RF were younger (p < 0.0001), more frequently males (p = 0.003), and less adherent (p < 0.0001) to secondary prophylaxis than patients without RF recurrence. Non-adherence to medication at any time during follow-up was detected in 35% of patients. Rates of non-adherence were higher in the group of patients that were lost to follow-up (42%) than in the group of patients still in follow-up (32%) (p = 0.027). Appointment frequency was inadequate in 10% of patients. Higher rates of inadequate appointment frequency were observed among patients who were eventually lost to follow-up (14.5%) than in patients who were successfully followed-up (8%) (p = 0.022). 180 patients (33.5%) were lost to follow up at some point in time.

Conclusions: We recommend implementation of a registry, and a system of active search of missing patients in every service responsible for the follow-up of RF patients. Measures to increase adherence to secondary prophylaxis need to be implemented formally, once non-adherence to secondary prophylaxis is the main cause of RF recurrence. Detection of irregularity in secondary prophylaxis or in appointments should be an alert about the possibility of loss of follow-up and closer observation should be instituted.

References

    1. II Consenso sobre Prevenção da Febre Reumática da Sociedade Brasileira de Pediatria. Correios da SBP. 2004;10:9–14.
    1. Rayamajhi A, Sharma D, Shakya U. First-episode versus recurrent acute rheumatic fever: is it different? Pediatr Int. 2009;51:269–75. doi: 10.1111/j.1442-200X.2008.02743.x.
    1. Carapetis JR, McDonald M, Wilson NJ. Acute rheumatic fever. Lancet. 2005;366:155–68. doi: 10.1016/S0140-6736(05)66874-2.
    1. Gerber MA, Baltimore RS, Eaton CB, Gewitz M, Rowley AH, Shulman ST, Taubert KA. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation. 2009;119:1541–51. doi: 10.1161/CIRCULATIONAHA.109.191959.
    1. Nordet P, Lopez R, Duenas A, Sarmiento L. Prevention and control of rheumatic fever and rheumatic heart disease: the Cuban experience (1986-1996-2002) Cardiovasc J Afr. 2008;19:135–40.
    1. Steer AC, Carapetis JR. Acute rheumatic fever and rheumatic heart disease in indigenous populations. Pediatr Clin North Am. 2009;56:1401–19. doi: 10.1016/j.pcl.2009.09.011.
    1. Carapetis JR, Currie BJ. Preventing rheumatic heart disease in Australia. Med J Aust. 1998;168:428–9.
    1. Carapetis JR, Mayosi BM, Kaplan EL. Controlling rheumatic heart disease in developing countries. Cardiovasc J S Afr. 2006;17:164–5.
    1. Carapetis JR. Rheumatic heart disease in developing countries. N Engl J Med. 2007;357:439–41. doi: 10.1056/NEJMp078039.
    1. Carapetis JR, Kilburn CJ, MacDonald KT, Walker AR, Currie BJ. Ten-year follow up of a cohort with rheumatic heart disease (RHD) Aust N Z J Med. 1997;27:691–7.
    1. Manyemba J, Mayosi BM. Penicillin for secondary prevention of rheumatic fever. Cochrane Database Syst Rev 3. 2002. p. CD002227.
    1. Guidelines for the diagnosis of rheumatic fever. Jones Criteria, 1992 update. Special Writing Group of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young of the American Heart Association. JAMA. 1992;268:2069–73. doi: 10.1001/jama.268.15.2069.
    1. Saxena A. Diagnosis of rheumatic fever: current status of Jones Criteria and role of echocardiography. Indian J Pediatr. 2000;67:S11–4.
    1. Stewart T, McDonald R, Currie B. Acute rheumatic fever: adherence to secondary prophylaxis and follow up of Indigenous patients in the Katherine region of the Northern Territory. Aust J Rural Health. 2007;15:234–40. doi: 10.1111/j.1440-1584.2007.00896.x.
    1. McDonald M, Brown A, Noonan S, Carapetis JR. Preventing recurrent rheumatic fever: the role of register based programmes. Heart. 2005;91:1131–3. doi: 10.1136/hrt.2004.057570.
    1. Kumar R. Controlling rheumatic heart disease in developing countries. World Health Forum. 1995;16:47–51.
    1. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA. 2002;288:2880–3. doi: 10.1001/jama.288.22.2880.
    1. Herdy GV. [The challenge of secondary prophylaxis in rheumatic fever] Arq Bras Cardiol. 1996;67:317.
    1. Kumar R, Thakur JS, Aggarwal A, Ganguly NK. Compliance of secondary prophylaxis for controlling rheumatic fever and rheumatic heart disease in a rural area of northern India. Indian Heart J. 1997;49:282–8.
    1. Robertson KA, Volmink JA, Mayosi BM. Lack of adherence to the national guidelines on the prevention of rheumatic fever. S Afr Med J. 2005;95:52–6.
    1. Ferrieri P. Proceedings of the Jones Criteria workshop. Circulation. 2002;106:2521–3. doi: 10.1161/01.CIR.0000037745.65929.FA.
    1. Meira ZM, Goulart EM, Colosimo EA, Mota CC. Long term follow up of rheumatic fever and predictors of severe rheumatic valvar disease in Brazilian children and adolescents. Heart. 2005;91:1019–22. doi: 10.1136/hrt.2004.042762.
    1. WHO programme for the prevention of rheumatic fever/rheumatic heart disease in 16 developing countries: report from Phase I (1986-90) WHO Cardiovascular Diseases Unit and principal investigators. Bull World Health Organ. 1992;70:213–8.
    1. Berrios X, del Campo E, Guzman B, Bisno AL. Discontinuing rheumatic fever prophylaxis in selected adolescents and young adults. A prospective study. Ann Intern Med. 1993;118:401–6.
    1. Bassili A, Zaher SR, Zaki A, Abdel-Fattah M, Tognoni G. Profile of secondary prophylaxis among children with rheumatic heart disease in Alexandria, Egypt. East Mediterr Health J. 2000;6:437–46.
    1. Ralph A, Jacups S, McGough K, McDonald M, Currie BJ. The challenge of acute rheumatic fever diagnosis in a high-incidence population: a prospective study and proposed guidelines for diagnosis in Australia's Northern Territory. Heart Lung Circ. 2006;15:113–8. doi: 10.1016/j.hlc.2005.08.006.
    1. Harrington Z, Thomas DP, Currie BJ, Bulkanhawuy J. Challenging perceptions of non-compliance with rheumatic fever prophylaxis in a remote Aboriginal community. Med J Aust. 2006;184:514–7.
    1. Macedo A, Primo M, Kaku S, Lima M, Sampayo EF. [Rheumatic cardiopathy in children. A comparative study in 2 consecutive 9-year periods] Acta Med Port. 1989;2:127–31.
    1. Eissa S, Lee R, Binns P, Garstone G, McDonald M. Assessment of a register-based rheumatic heart disease secondary prevention program in an Australian Aboriginal community. Aust N Z J Public Health. 2005;29:521–5. doi: 10.1111/j.1467-842X.2005.tb00243.x.
    1. Naim M, Tjipta GD, Siregar AA, Halim S. Rheumatic fever and rheumatic heart disease at the Department of Child Health, School of Medicine, University of North Sumatera/Dr. Pirngadi Hospital, Medan (1983-1985) Paediatr Indones. 1989;29:64–71.
    1. Mincham CMMD, Plant AJ. The quality of management of rheumatic fever/heart disease in the Kimberley. Aust N Z J Public Health. 2002;26:417–20. doi: 10.1111/j.1467-842X.2002.tb00340.x.
    1. Gubert ICKL, Vizzotto AO Junior, Leão MTC. Critical evaluation of diagnostic and secondary prophylaxis in 259 cases of rheumatic fever. Rev Med Paraná. 1997;54:48–54.
    1. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA. 2002;288:2868–79. doi: 10.1001/jama.288.22.2868.
    1. Herdy GV, Souza DC, Barros PB, Pinto CA. [Secondary prophylaxis in rheumatic fever. Oral antibiotic therapy versus benzathine penicillin] Arq Bras Cardiol. 1996;67:331–3.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe